BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 3, 2015--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that it will
report its financial results for the fourth quarter and full year ended
December 31, 2014, on Tuesday, March 10, 2015. Following distribution of
the earnings release via wire services, the Ocular management team will
host a live conference call and webcast at 8:00 a.m. Eastern Time to
review the Company's financial results and provide a business update.
The live webcast can be accessed by visiting the investor section of
Ocular’s website at investors.ocutx.com.
Please connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call 844-464-3934
(U.S.) or 765-507-2620 (International) to listen to the conference call.
The conference ID number for the live call will be 98833560. An archive
of the webcast will be available until March 24, 2015 on the company’s
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix's lead product candidates are in Phase 3
clinical development for post-surgical ocular inflammation and pain, and
Phase 2 clinical development for glaucoma, allergic conjunctivitis, and
dry eye disease. The Company is also evaluating sustained-release
injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular
Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal
corneal incisions following cataract surgery.
Source: Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
McClellan on behalf of Ocular Therapeutix
Vice President of Sales and Marketing